Novel Calcitriol Analogs

Abstract (Set) Five to eight million people in the US and 125 million people worldwide have psoriasis. Current treatment of Psoriasis includes Maxacalcitol, an oxa analog of calcitriol which is a necessary regulatory steroid hormone. Scientists at JHU have rationally designed and easily synthesized eight new oxa analogs of the natural hormone calcitriol. Three of the new analogs are more antiproliferative in vitro and desirably less calcemic in vivo than the natural hormone. Of these three, one has transcriptional potency almost as high as that of calcitriol. Preliminary studies support a substantial therapeutic widow comparing favorably with Maxacalcitol. Additional studies indicate a shorter half-life for one of the newly designed and synthesized oxa analogs offering a potential therapeutic advantage in minimizing any undesirable calciuric activity, as is the case for a current antipsoriasis topical. Description (Set) Proposed Use (Set) This invention provides a potential therapeutic for chemotherapy of psoriasis that may have an advantage over currently used topical treatments and may be a candidate for chemotherapy of hyperparathyroidism.

Inventor(s): Posner, Gary H. ,Petersen, Kimberly

Type of Offer: Licensing



« More Medical Devices Patents

---